Evidence map›Paper›PMID 34169381›Full record

Trial reportCardiovascular drugs and therapy2022

RIC in COVID-19-a Clinical Trial to Investigate Whether Remote Ischemic Conditioning (RIC) Can Prevent Deterioration to Critical Care in Patients with COVID-19.

Sean M Davidson, Kishal Lukhna, Diana A Gorog, Alan D Salama, Alejandro Rosell Castillo, Sara Giesz, Pelin Golforoush, Siavash Beikoghli Kalkhoran, Sandrine Lecour, Aqeela Imamdin and 6 more

Erratum issued Registry-linked trialOpen access · hybridAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cardiovascular drugs and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04699227 (CAN REMOTE ISCHAEMIC CONDITIONING REDUCE INFLAMMATORY MARKERS IN COVID-19 PATIENTS - A MULTI-SITE, RANDOMISED PILOT STUDY), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04699227 nacompletednot on this map

Can remote ischaemic conditioning reduce inflammatory markers in covid-19 patients - a multi-site, randomised pilot study

TypeinterventionalSponsorDerek YellonRan2021 to 2021Enrolled40ConditionsCovid19, IschemiaArmsCuff application with inflation, Sham inflation
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 3 countries.

Sean M DavidsonThe Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, London, WC1E 6HX, UK.
Kishal LukhnaDivision of Cardiology, Groote Schuur Hospital and Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Diana A GorogPostgraduate Medicine, University of Hertfordshire, UK & East and North Hertfordshire NHS Trust, Stevenage, Hertfordshire, UK.
Alan D SalamaDepartment of Renal Medicine, Royal Free Hospital, London, UK.
Alejandro Rosell CastilloAtherosclerosis and Vascular Biology Laboratory, State University of Campinas, Campinas, Brazil.
Sara GieszThe Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, London, WC1E 6HX, UK.
Pelin GolforoushThe Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, London, WC1E 6HX, UK.
Siavash Beikoghli KalkhoranThe Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, London, WC1E 6HX, UK.
Sandrine LecourThe Hatter Institute for Cardiovascular Research, University of Cape Town, Cape Town, South Africa.
Aqeela ImamdinThe Hatter Institute for Cardiovascular Research, University of Cape Town, Cape Town, South Africa.
Helison R P do CarmoAtherosclerosis and Vascular Biology Laboratory, State University of Campinas, Campinas, Brazil.
Ticiane Gonçalez BoviAtherosclerosis and Vascular Biology Laboratory, State University of Campinas, Campinas, Brazil.
Mauricio W PerroudAtherosclerosis and Vascular Biology Laboratory, State University of Campinas, Campinas, Brazil.
Mpiko NtsekheDivision of Cardiology, Groote Schuur Hospital and Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Andrei C SpositoAtherosclerosis and Vascular Biology Laboratory, State University of Campinas, Campinas, Brazil.
Derek M YellonThe Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, London, WC1E 6HX, UK. d.yellon@ucl.ac.uk.
Universidade Estadual de Campinas (UNICAMP) · BRUniversity College London · GBGroote Schuur Hospital · ZAUniversity of Cape Town · ZAThe Royal Free Hospital · GBUniversity of Hertfordshire · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCoronavirus disease 19 (COVID-19) has, to date, been diagnosed in over 130 million persons worldwide and is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Several variants of concern have emerged including those in the United Kingdom, South Africa, and Brazil. SARS-CoV-2 can cause a dysregulated inflammatory response known as a cytokine storm, which can progress rapidly to acute respiratory distress syndrome (ARDS), multi-organ failure, and death. Suppressing these cytokine elevations may be key to improving outcomes. Remote ischemic conditioning (RIC) is a simple, non-invasive procedure whereby a blood pressure cuff is inflated and deflated on the upper arm for several cycles. "RIC in COVID-19" is a pilot, multi-center, randomized clinical trial, designed to ascertain whether RIC suppresses inflammatory cytokine production.

methodsA minimum of 55 adult patients with diagnosed COVID-19, but not of critical status, will be enrolled from centers in the United Kingdom, Brazil, and South Africa. RIC will be administered daily for up to 15 days. The primary outcome is the level of inflammatory cytokines that are involved in the cytokine storm that can occur following SARS-CoV-2 infection. The secondary endpoint is the time between admission and until intensive care admission or death. The in vitro cytotoxicity of patient blood will also be assessed using primary human cardiac endothelial cells.

conclusionsThe results of this pilot study will provide initial evidence on the ability of RIC to suppress the production of inflammatory cytokines in the setting of COVID-19.

trial registrationNCT04699227, registered January 7th, 2021.

Indexed as

COVID-19AdultCritical CareCytokine Release SyndromeCytokinesEndothelial CellsHumansPilot ProjectsSARS-CoV-2Treatment OutcomeCytokinesClinical trialCOVID-19CytokinesEndothelial cellsImmunosuppressionRemote ischemic conditioning

Identifiers

PMID34169381
PMCPMC8225459
OpenAlexW4205419964

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.